GlobeNewswire Inc.··The Rosen Law FirmImmutep Stock Plummets 82.6% After Failed Phase III Trial for Lead Cancer Drug
Immutep's stock crashed to $0.48 after its independent monitoring committee halted the TACTI-004 Phase III trial for eftilagimod alfa due to futility, prompting legal investigation.
IMMPinvestor lossessecurities class action